Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

1.

Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides.

Fang B, Hoffman MA, Mirza AS, Mishall KM, Li J, Peterman SM, Smalley KS, Shain KH, Weinberger PM, Wu J, Rix U, Haura EB, Koomen JM.

Methods. 2015 Mar 14. pii: S1046-2023(15)00100-0. doi: 10.1016/j.ymeth.2015.03.006. [Epub ahead of print]

PMID:
25782629
2.

Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma.

Schneeberger VE, Ren Y, Luetteke N, Huang Q, Chen L, Lawrence HR, Lawrence NJ, Haura EB, Koomen JM, Coppola D, Wu J.

Oncotarget. 2015 Mar 20;6(8):6191-202.

3.

Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine.

Baldelli E, Haura EB, Crinò L, Cress DW, Ludovini V, Schabath MB, Liotta LA, Petricoin EF, Pierobon M.

Proteomics Clin Appl. 2015 Feb 11. doi: 10.1002/prca.201400056. [Epub ahead of print]

PMID:
25676683
4.

Interleukin polymorphisms associated with overall survival, disease-free survival, and recurrence in non-small cell lung cancer patients.

Woods NT, Monteiro AN, Thompson ZJ, Amankwah EK, Naas N, Haura EB, Beg AA, Schabath MB.

Mol Carcinog. 2015 Jan 18. doi: 10.1002/mc.22275. [Epub ahead of print]

PMID:
25597281
5.

Annotation of human cancers with EGFR signaling-associated protein complexes using proximity ligation assays.

Smith MA, Hall R, Fisher K, Haake SM, Khalil F, Schabath MB, Vuaroqueaux V, Fiebig HH, Altiok S, Chen YA, Haura EB.

Sci Signal. 2015 Jan 13;8(359):ra4. doi: 10.1126/scisignal.2005906.

PMID:
25587191
6.

Transforming growth factor β signaling overcomes dasatinib resistance in lung cancer.

Gordian E, Li J, Pevzner Y, Mediavilla-Varela M, Luddy K, Ohaegbulam K, Daniel KG, Haura EB, Muñoz-Antonia T.

PLoS One. 2014 Dec 11;9(12):e114131. doi: 10.1371/journal.pone.0114131. eCollection 2014.

7.

Role of LKB1-CRTC1 on glycosylated COX-2 and response to COX-2 inhibition in lung cancer.

Cao C, Gao R, Zhang M, Amelio AL, Fallahi M, Chen Z, Gu Y, Hu C, Welsh EA, Engel BE, Haura EB, Cress WD, Wu L, Zajac-Kaye M, Kaye FJ.

J Natl Cancer Inst. 2014 Dec 1;107(1):358. doi: 10.1093/jnci/dju358. Print 2015 Jan.

PMID:
25465874
8.

Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.

Bai Y, Kim JY, Watters JM, Fang B, Kinose F, Song L, Koomen JM, Teer JK, Fisher K, Chen YA, Rix U, Haura EB.

Cancer Res. 2014 Dec 15;74(24):7217-28. doi: 10.1158/0008-5472.CAN-14-0505. Epub 2014 Oct 27.

PMID:
25348954
9.

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.

Villaruz LC, Socinski MA, Abberbock S, Berry LD, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Varella-Garcia M, Franklin WA, Camidge DR, Sequist LV, Haura EB, Ladanyi M, Kurland BF, Kugler K, Minna JD, Bunn PA, Kris MG.

Cancer. 2015 Feb 1;121(3):448-56. doi: 10.1002/cncr.29042. Epub 2014 Oct 1.

PMID:
25273224
10.

Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing.

Haura EB, Rix U.

J Natl Cancer Inst. 2014 Sep 10;106(9). pii: dju250. doi: 10.1093/jnci/dju250. Print 2014 Sep. No abstract available.

PMID:
25214562
11.

Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics.

Gridling M, Ficarro SB, Breitwieser FP, Song L, Parapatics K, Colinge J, Haura EB, Marto JA, Superti-Furga G, Bennett KL, Rix U.

Mol Cancer Ther. 2014 Nov;13(11):2751-62. doi: 10.1158/1535-7163.MCT-14-0152. Epub 2014 Sep 4.

PMID:
25189542
12.

Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer.

Song L, Smith MA, Doshi P, Sasser K, Fulp W, Altiok S, Haura EB.

J Thorac Oncol. 2014 Jul;9(7):974-82. doi: 10.1097/JTO.0000000000000193.

PMID:
24922005
13.

Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.

Yoshida T, Zhang G, Smith MA, Lopez AS, Bai Y, Li J, Fang B, Koomen J, Rawal B, Fisher KJ, Chen AY, Kitano M, Morita Y, Yamaguchi H, Shibata K, Okabe T, Okamoto I, Nakagawa K, Haura EB.

Clin Cancer Res. 2014 Aug 1;20(15):4059-74. doi: 10.1158/1078-0432.CCR-13-1559. Epub 2014 Jun 11.

PMID:
24919575
14.

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA.

JAMA. 2014 May 21;311(19):1998-2006. doi: 10.1001/jama.2014.3741.

15.

The ethical imperative of risk disclosure in research: the answer is always yes.

Quinn GP, Haura EB, Murphy D.

Am J Bioeth. 2014 Apr;14(4):18-9. doi: 10.1080/15265161.2014.889242. No abstract available.

PMID:
24730484
16.

TGF-β-inducible microRNA-183 silences tumor-associated natural killer cells.

Donatelli SS, Zhou JM, Gilvary DL, Eksioglu EA, Chen X, Cress WD, Haura EB, Schabath MB, Coppola D, Wei S, Djeu JY.

Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4203-8. doi: 10.1073/pnas.1319269111. Epub 2014 Feb 28.

17.

SHP2E76K mutant promotes lung tumorigenesis in transgenic mice.

Schneeberger VE, Luetteke N, Ren Y, Berns H, Chen L, Foroutan P, Martinez GV, Haura EB, Chen J, Coppola D, Wu J.

Carcinogenesis. 2014 Aug;35(8):1717-25. doi: 10.1093/carcin/bgu025. Epub 2014 Jan 30.

PMID:
24480804
18.

Stakeholder perceptions of thoracic rapid tissue donation: An exploratory study.

McIntyre J, Pratt C, Pentz RD, Haura EB, Quinn GP; FORWARD.

Soc Sci Med. 2013 Dec;99:35-41. doi: 10.1016/j.socscimed.2013.08.035. Epub 2013 Sep 6.

19.

Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer.

Chiappori A, Williams C, Northfelt DW, Adams JW, Malik S, Edelman MJ, Rosen P, Van Echo DA, Berger MS, Haura EB.

J Thorac Oncol. 2014 Jan;9(1):121-5. doi: 10.1097/JTO.0000000000000027.

PMID:
24346101
20.

GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells.

Remsing Rix LL, Kuenzi BM, Luo Y, Remily-Wood E, Kinose F, Wright G, Li J, Koomen JM, Haura EB, Lawrence HR, Rix U.

ACS Chem Biol. 2014 Feb 21;9(2):353-8. doi: 10.1021/cb400660a. Epub 2013 Nov 20.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk